The Efficacy of Bevacizumab in Ovarian Cancer and Its Influence on the Levels of Serum CA125, HE4, CEA and TPA
Journal: Journal of Clinical Medicine Research DOI: 10.32629/jcmr.v6i1.3674
Abstract
This paper aims to study the virtue of bevacizumab in the therapy of epithelial ovarian cancer and its impact on the levels of blood serum carbohydrate antigen 125 (CA125), tissue polypeptide antigen (TPA), human epididymis protein 4 (HE4) and carcinoembryonic antigen (CEA). Methods: To analyze the medical records of 60 patients with ovarian cancer who were hpspitalized in the First Hospital of Shanxi Medical University from April 2023 to April 2024 retrospectively. The sick persons were randomly divided into two groups: observs (n=30) with controls (n=30) based on the seperate treatment drugs. The control sick persons were treated with the TC regimen of paclitaxel and carboplatin, while the observe sick persons were treated in combined treatment with bevacizumab. The treatment course was 6 cycles. The efficacy, immune function, and changes in serum CA125, HE4, CEA, and TPA levels were compared between the two seperate groups, and the occurrence of toxic side effects during the treatment period was recorded. Results: The total effective rate and immune function levels of the observes after treatment were higher than those of the control sick persons, and the levels of CA125, HE4, CEA, and TPA in the blood serum were lower than those of the control sick persons (P<0.05); there was statistically meaningless in the total incidence of toxic side effects between the observs with controls during the treatment period (P>0.05). Conclusion: Bevacizumab has a oustanding therapeutic effect on ovarian cancer, effectively improving immune function and reducing the expression of serum CA125, HE4, CEA and TPA.
Keywords
Ovarian cancer; Bevacizumab; Paclitaxel and carboplatin; Tumor markers; Tissue polypeptide antigen
Full Text
PDF - Viewed/Downloaded: 0 TimesReferences
[1]Penny SM. Ovarian Cancer: An Overview. Radiol Technol. 2020 Jul;91(6):561-575.
[2]Bryant A, Hiu S, Kunonga PT, Gajjar K, Craig D, Vale L, Winter-Roach BA, Elattar A, Naik R. Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery. Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2.
[3] Anadon CM, Yu X, Hänggi K, Biswas S, Chaurio RA, Martin A, Payne KK, Mandal G, Innamarato P, Harro CM, Mine JA, Sprenger KB, Cortina C, Powers JJ, Costich TL, Perez BA, Gatenbee CD, Prabhakaran S, Marchion D, Heemskerk MHM, Curiel TJ, Anderson AR, Wenham RM, Rodriguez PC, Conejo-Garcia JR. Ovarian cancer immunogenicity is governed by a narrow subset of progenitor tissue-resident memory T cells. Cancer Cell. 2022 May 9;40(5):545-557.e13. doi: 10.1016/j.ccell.2022.03.008. Epub 2022 Apr 14.
[4] Khanmammadov NJ, Doğan İ, Okay NS, Azizy A, Saip P, Aydiner A. Comparative analysis of doublet chemotherapy regimens plus bevacizumab in patients with recurrent ovarian cancer. Medicine (Baltimore). 2024 Jan 5;103(1):e36750. doi: 10.1097/MD.0000000000036750. PMID: 38181291.
[5] Zhang M, Cheng S, Jin Y, Zhao Y, Wang Y. Roles of CA125 in diagnosis, prediction, and oncogenesis of ovarian cancer. Biochim Biophys Acta Rev Cancer. 2021 Apr;1875(2):188503. doi: 10.1016/j.bbcan.2021.188503. Epub 2021 Jan 7.
[6] Anastasi E, Farina A, Granato T, Colaiacovo F, Pucci B, Tartaglione S, Angeloni A. Recent Insight about HE4 Role in Ovarian Cancer Oncogenesis. Int J Mol Sci. 2023 Jun 22;24(13):10479. doi: 10.3390/ijms241310479.
[7]Wan Q, Liu Y, Lv B, Chen X. Correlation of Molecular Tumor Markers CA125, HE4, and CEA with the Development and Progression of Epithelial Ovarian Cancer. Iran J Public Health. 2021 Jun;50(6):1197-1205. doi: 10.18502/ijph.v50i6.6418.
[8] Schröder L, Domroese CM, Rupp ABA, Gihr KME, Niederau C, Mallmann MR, Holdenrieder S. Clinical Applicability of Tissue Polypeptide Antigen and CA-125 in Gynecological Malignancies. Biomedicines. 2023 Nov 2;11(11):2960. doi: 10.3390/biomedicines11112960.
[9] Reid B.M., Permuth J.B., Sellers T.A. Epidemiology of ovarian cancer: A review. Cancer Biol. Med. 2017;14:9–32. doi: 10.20892/j.issn.2095-3941.2016.0084.
[10]Nowak M, Klink M. The Role of Tumor-Associated Macrophages in the Progression and Chemoresistance of Ovarian Cancer. Cells. 2020 May 22;9(5):1299. doi: 10.3390/cells9051299.
[11] Pfisterer J, Shannon CM, Baumann K, Rau J, Harter P, Joly F, Sehouli J, Canzler U, Schmalfeldt B, Dean AP, Hein A, Zeimet AG, Hanker LC, Petit T, Marmé F, El-Balat A, Glasspool R, de Gregorio N, Mahner S, Meniawy TM, Park-Simon TW, Mouret-Reynier MA, Costan C, Meier W, Reinthaller A, Goh JC, L'Haridon T, Baron Hay S, Kommoss S, du Bois A, Kurtz JE; AGO-OVAR 2.21/ENGOT-ov 18 Investigators. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial. Lancet Oncol. 2020 May;21(5):699-709. doi: 10.1016/S1470-2045(20)30142-X. Epub 2020 Apr 16. Erratum in: Lancet Oncol. 2022 Jun;23(6):e248. doi: 10.1016/S1470-2045(22)00303-5.
[12] Lu Y, Yao Y, Zhai S, Ni F, Wang J, Chen F, Zhang Y, Li H, Hu H, Zhang H, Yu B, Chen H, Huang X, Ding W, Lu D. The role of immune cell signatures in the pathogenesis of ovarian-related diseases: a causal inference based on Mendelian randomization. Int J Surg. 2024 Oct 1;110(10):6541-6550. doi: 10.1097/JS9.0000000000001814.
[13] Nakai H, Matsumura N. The roles and limitations of bevacizumab in the treatment of ovarian cancer. Int J Clin Oncol. 2022 Jul;27(7):1120-1126. doi: 10.1007/s10147-022-02169-x. Epub 2022 Apr 27.
[2]Bryant A, Hiu S, Kunonga PT, Gajjar K, Craig D, Vale L, Winter-Roach BA, Elattar A, Naik R. Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery. Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2.
[3] Anadon CM, Yu X, Hänggi K, Biswas S, Chaurio RA, Martin A, Payne KK, Mandal G, Innamarato P, Harro CM, Mine JA, Sprenger KB, Cortina C, Powers JJ, Costich TL, Perez BA, Gatenbee CD, Prabhakaran S, Marchion D, Heemskerk MHM, Curiel TJ, Anderson AR, Wenham RM, Rodriguez PC, Conejo-Garcia JR. Ovarian cancer immunogenicity is governed by a narrow subset of progenitor tissue-resident memory T cells. Cancer Cell. 2022 May 9;40(5):545-557.e13. doi: 10.1016/j.ccell.2022.03.008. Epub 2022 Apr 14.
[4] Khanmammadov NJ, Doğan İ, Okay NS, Azizy A, Saip P, Aydiner A. Comparative analysis of doublet chemotherapy regimens plus bevacizumab in patients with recurrent ovarian cancer. Medicine (Baltimore). 2024 Jan 5;103(1):e36750. doi: 10.1097/MD.0000000000036750. PMID: 38181291.
[5] Zhang M, Cheng S, Jin Y, Zhao Y, Wang Y. Roles of CA125 in diagnosis, prediction, and oncogenesis of ovarian cancer. Biochim Biophys Acta Rev Cancer. 2021 Apr;1875(2):188503. doi: 10.1016/j.bbcan.2021.188503. Epub 2021 Jan 7.
[6] Anastasi E, Farina A, Granato T, Colaiacovo F, Pucci B, Tartaglione S, Angeloni A. Recent Insight about HE4 Role in Ovarian Cancer Oncogenesis. Int J Mol Sci. 2023 Jun 22;24(13):10479. doi: 10.3390/ijms241310479.
[7]Wan Q, Liu Y, Lv B, Chen X. Correlation of Molecular Tumor Markers CA125, HE4, and CEA with the Development and Progression of Epithelial Ovarian Cancer. Iran J Public Health. 2021 Jun;50(6):1197-1205. doi: 10.18502/ijph.v50i6.6418.
[8] Schröder L, Domroese CM, Rupp ABA, Gihr KME, Niederau C, Mallmann MR, Holdenrieder S. Clinical Applicability of Tissue Polypeptide Antigen and CA-125 in Gynecological Malignancies. Biomedicines. 2023 Nov 2;11(11):2960. doi: 10.3390/biomedicines11112960.
[9] Reid B.M., Permuth J.B., Sellers T.A. Epidemiology of ovarian cancer: A review. Cancer Biol. Med. 2017;14:9–32. doi: 10.20892/j.issn.2095-3941.2016.0084.
[10]Nowak M, Klink M. The Role of Tumor-Associated Macrophages in the Progression and Chemoresistance of Ovarian Cancer. Cells. 2020 May 22;9(5):1299. doi: 10.3390/cells9051299.
[11] Pfisterer J, Shannon CM, Baumann K, Rau J, Harter P, Joly F, Sehouli J, Canzler U, Schmalfeldt B, Dean AP, Hein A, Zeimet AG, Hanker LC, Petit T, Marmé F, El-Balat A, Glasspool R, de Gregorio N, Mahner S, Meniawy TM, Park-Simon TW, Mouret-Reynier MA, Costan C, Meier W, Reinthaller A, Goh JC, L'Haridon T, Baron Hay S, Kommoss S, du Bois A, Kurtz JE; AGO-OVAR 2.21/ENGOT-ov 18 Investigators. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial. Lancet Oncol. 2020 May;21(5):699-709. doi: 10.1016/S1470-2045(20)30142-X. Epub 2020 Apr 16. Erratum in: Lancet Oncol. 2022 Jun;23(6):e248. doi: 10.1016/S1470-2045(22)00303-5.
[12] Lu Y, Yao Y, Zhai S, Ni F, Wang J, Chen F, Zhang Y, Li H, Hu H, Zhang H, Yu B, Chen H, Huang X, Ding W, Lu D. The role of immune cell signatures in the pathogenesis of ovarian-related diseases: a causal inference based on Mendelian randomization. Int J Surg. 2024 Oct 1;110(10):6541-6550. doi: 10.1097/JS9.0000000000001814.
[13] Nakai H, Matsumura N. The roles and limitations of bevacizumab in the treatment of ovarian cancer. Int J Clin Oncol. 2022 Jul;27(7):1120-1126. doi: 10.1007/s10147-022-02169-x. Epub 2022 Apr 27.
Copyright © 2025 Liqiang Han
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
